TENT AND TRADEMARK OFFICE IN THE UNITE

Genoveffa Franchini Jeffrey S. Parkin Examiner: Applicant:

Serial No.: 10/048,072 Group Art Unit: 1648

Docket: 1662.018US1 Filed: January 25, 2002 Immunotherapy In HIV Infected Persons Using Vaccines After Multi-Drug Title:

Treatment

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants hereby authorize the Commissoner to charge the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p), to Deposit Account No. 19-0743. Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743. Serial No :10/048,072

Filing Date: January 25, 2002

Title: Immunotherapy In HIV Infected Persons Using Vaccines After Multi-Drug Treatment

Page 2 Dkt: 1662.018US1

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

GENOVEFFA FRANCHINI ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938
Minneapolis, MN 55402
(516) 795-6820

Date August 28,2006

Robin A. Chadwick Reg. No. 36,477

<u>CERTIFICATE UNDER 37 CFR 1.8:</u> The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this <u>28th</u> day of <u>August</u>, 2006.

CANDIS BUENDING

Name

Signature

PTO/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademerk Office: U.S. DEPARTMENT OF COMMERCE
ection of information unless it contains a valid OMB control number. SEP U & 2005 Substitute for form 1449A/PTO
INFORMATION DISCLOSURE
INFORMATION BY APPLICANT

ADEMI Complete if Known Application Number 10/048,072 January 25, 2002 (Use as many sheets as necessary) Filing Date **First Named Inventor** Franchini, Genoveffa **Group Art Unit** 1648 Parkin, Jeffrey **Examiner Name** SEP Va 2006 A TRADEMART Attorney Docket No: 1662.018US1 Sheet 1 of 1

	US PATENT DOCUMENTS							
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate				

FOREIGN PATENT DOCUMENTS							
Examiner	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited	T ²			
Initials*		1 ablication bate	Document				

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		FRIEDRICH, T., et al., "The rule of the SIV Model in AIDS vaccine research",	
		IAVI Report, Vol. 9, No. 2,(June 14, 2005),5 pages	
		HEL, Z., "Improved Vaccine Protection from Simian AIDS by the Addition of	
		Nonstructural Simian Immunodeficiency Virus Genes", The Journal of	
		Immunology, 176, (2006),85-96	
		HIRSCH, V., "What can natural infection of African monkeys with simian	
		immunodeficiency virus tell us about the pathogenesis of AIDS?", AIDS Rev.,	
		6(1), (JanMar., 2004),40-53	
J M		LU, S., et al., "Simian Immunodeficiency Virus DNA Vaccine", Journal of	
		Virology, 70:6, 0022-538X/96/\$04.00+0,(June 1996),pp. 3978-3991	
		MUTHUMANI, K., et al., "A Gag-Pol/Env-Rev SIV239 DNA vaccine improves	
		CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251	
		challenge in rhesus Macaques", Vaccine, 21(7-8), (Jan. 30, 2003),629-37	
		PHILIPP, M. T., et al., "Experimental infection of rhesus macaques with	
		Streptococcus pneumoniae: a possible model for vaccine assessment", <u>J Med</u>	
		Primatol., 35(3), (June, 2006),113-22	
		SAUTER, S. L., "Non-Replicating Viral Vector-Based AIDS Vaccines: Interplay	
		Between Viral Vectors and the Immune System", Current HIV research, 3(2),	
		(Apr., 2005),157-181	
		SUN, W., et al., "Protection of Rhesus monkeys against dengue virus challenge	
		after tetravalent live attenuated dengue virus vaccination", J Infect Dis., 193(12),	
		(June 15, 2006),1658-65	

EXAMINER

DATE CONSIDERED